Abstract
Immunotherapy treatments have demonstrated a wide variety of treatment response patterns, and noninvasive ways to monitor these responses are greatly needed. Molecular imaging, in particular using positron emission tomography (PET), has emerged as an attractive way to confront this problem. Using highly specific antibody probes, immunoPET has enabled clear visualization of many immunologically relevant markers in vivo in preclinical models, including checkpoint molecules, T-cell markers, and immune activation biomarkers. While clinical results have yet to be published, these emerging techniques are expected to have an impact for patients in the near future.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ehlerding EB, England CG, McNeel DG, Cai W. Molecular imaging of immunotherapy targets in cancer. J Nucl Med. 2016;57(10):1487–92.
Wei W, Jiang D, Ehlerding EB, Luo Q, Cai W. Noninvasive PET imaging of T cells. Trends Cancer. 2018;4(5):359–73.
Mayer AT, Gambhir SS. The immunoimaging toolbox. J Nucl Med. 2018;59(8):1174–82.
Brandt M, Cardinale J, Aulsebrook ML, Gasser G, Mindt TL. An overview of PET radiochemistry, part 2: radiometals. J Nucl Med. 2018;59(10):1500–6.
Boros E, Holland JP. Chemical aspects of metal ion chelation in the synthesis and application antibody-based radiotracers. J Label Compd Radiopharm. 2018;61(9):652–71.
Higashikawa K, Yagi K, Watanabe K, Kamino S, Ueda M, Hiromura M, et al. (64)Cu-DOTA-anti-CTLA-4 mAb enabled PET visualization of CTLA-4 on the T-cell infiltrating tumor tissues. PLoS One. 2014;9(11):e109866.
England CG, Jiang D, Ehlerding EB, Rekoske BT, Ellison PA, Hernandez R, et al. 89Zr-labeled nivolumab for imaging of T-cell infiltration in a humanized murine model of lung cancer. Eur J Nucl Med Mol Imaging. 2018;45(1):110–20.
Hecht M, Büttner-Herold M, Erlenbach-Wünsch K, Haderlein M, Croner R, Grützmann R, et al. PD-L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable prognosis. Eur J Cancer. 2016;65:52–60.
Derer A, Spiljar M, Bäumler M, Hecht M, Fietkau R, Frey B, et al. Chemoradiation increases PD-L1 expression in certain melanoma and glioblastoma cells. Front Immunol. 2016;7:610.
Yang H, Bueso-Ramos C, DiNardo C, Estecio MR, Davanlou M, Geng Q-R, et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia. 2014;28(6):1280–8.
Truillet C, Oh HLJ, Yeo SP, Lee C-Y, Huynh LT, Wei J, et al. Imaging PD-L1 expression with immunoPET. Bioconjug Chem. 2018;29(1):96–103.
Kikuchi M, Clump DA, Srivastava RM, Sun L, Zeng D, Diaz-Perez JA, et al. Preclinical immunoPET/CT imaging using Zr-89-labeled anti-PD-L1 monoclonal antibody for assessing radiation-induced PD-L1 upregulation in head and neck cancer and melanoma. Oncoimmunology. 2017;6(7):e1329071.
Hettich M, Braun F, Bartholoma MD, Schirmbeck R, Niedermann G. High-resolution PET imaging with therapeutic antibody-based PD-1/PD-L1 checkpoint tracers. Theranostics. 2016;6(10):1629–40.
Rashidian M, Ingram JR, Dougan M, Dongre A, Whang KA, LeGall C, et al. Predicting the response to CTLA-4 blockade by longitudinal noninvasive monitoring of CD8 T cells. J Exp Med. 2017;214(8):2243–55.
Larimer BM, Wehrenberg-Klee E, Caraballo A, Mahmood U. Quantitative CD3 PET imaging predicts tumor growth response to anti-CTLA-4 therapy. J Nucl Med. 2016;57(10):1607–11.
Alam IS, Mayer AT, Sagiv-Barfi I, Wang K, Vermesh O, Czerwinski DK, et al. Imaging activated T cells predicts response to cancer vaccines. J Clin Invest. 2018;128(6):2569–80.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Ehlerding, E.B., Cai, W. (2020). ImmunoPET: The Future of Response Evaluation for Cancer Immunotherapy. In: Lopci, E., Fanti, S. (eds) Atlas of Response to Immunotherapy. Springer, Cham. https://doi.org/10.1007/978-3-030-31113-1_11
Download citation
DOI: https://doi.org/10.1007/978-3-030-31113-1_11
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-31112-4
Online ISBN: 978-3-030-31113-1
eBook Packages: MedicineMedicine (R0)